Skip to main content
Premium Trial:

Request an Annual Quote

Microbiologics SARS-CoV-2 RNA Process Control

Microbiologics has launched two new research-use-only products for COVID-19 research and quality control: a protein-coated RNA process control and an IVD control with pooled gene targets.

The new SARS-CoV-2 control features diagnostically relevant RNA sequences protected by phage protein, providing nuclease resistance even in nuclease-rich environments such as nasal secretions or plasma. This coating protects the RNA during the extraction process, preventing the false negatives that can occur with the use of naked RNA. The protein coating functions like the virus's protective envelope that sequesters and protects its RNA genome. Featuring genomic targets for all seven WHO COVID-19 testing protocols, this process control can be used for SARS-CoV-2 assay development, positive extraction, and spike-in controls.

The new SARS-CoV-2 Helix Elite control features a pool of large RNA molecules that match the viral sequences for the RdRp gene, S gene, E gene, and N gene. These pooled genetic targets offer broad compatibility with CDC- and WHO-specified test components to generate positive PCR signals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.